Pfizergan Would Have Challenged Novartis For 2015 Approvals Crown
Executive Summary
Novartis had the most new molecular entity approvals in 2015 with four, all developed in house; next in line is Allergan, with three approvals that stem from acquisitions and licensing.
You may also be interested in...
No Dominant Sponsors In US FDA's 2016 Novel Approvals Class
No company received more than two approvals among the 28 novel agents approved in 2016 by US FDA's drug and biologics centers combined.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.